Mindpeak sets standards with PD-L1 Cell Atlas
(PresseBox) (Hamburg, ) Europe’s leading provider of AI software for pathology, Mindpeak (Hamburg), has announced groundbreaking work with leading expert pathologists to improve AI-assisted cancer diagnosis. The collaboration on a “PD-L1 Cell Atlas” marks a significant step in medical research and helps to advance the development and application of Artificial Intelligence (AI) in oncology biomarker readout for precision medicine.
A refined approach for AI-assisted cancer diagnosis was developed by setting standards in the interpretation of scoring guidelines with a “PD-L1 Cell Atlas”, leading to improved interreader concordance among pathologists. This cell atlas will not only increase accuracy in the development of AI software for PD-L1 biomarker scoring, but will ultimately lead to better patient selection for more efficient immunotherapy using precision medicine drugs. The collaboration results were presented at ECP 2023, including the following authors: Prof. Sunil Badve (Winship Cancer Institute, Emory University Atlanta GA); Dr. George L. Kumar and Dr. Maria Karasarides (Bristol Myers Squibb Princeton NJ); Prof. Joseph Rüschoff and Prof. Hans-Ulrich Schildhaus (Discovery Life Sciences Biomarker Services GmbH Kassel); Dr. Tobias Lang, Felix Faber and Dr. Khalid Daifalla (Mindpeak GmbH Hamburg).
The pathologists’ expertise, particularly in difficult cases where distinguishing between cancer cells and immune cells is challenging, was combined with Mindpeak’s leading expertise in AI software for biomarker scoring and was integrated into Mindpeak’s AI software. This unique knowledge exchange between human experience and AI technology has significantly increased the effectiveness of cancer diagnosis.
Felix Faber, founder and CEO of Mindpeak, expressed his satisfaction with the groundbreaking collaboration: “I am very pleased that together with these outstanding experts we are able to contribute to the even better and more efficient application of AI in cancer diagnostics and the development of cancer therapies. This pioneering work forms an essential basis for the entire development of AI-assisted cancer treatment.”
The results of the study have been presented at the 35th European Congress of Pathology from 9-13 September in Dublin under the title “A roadmap for single-cell annotation using artificial intelligence algorithms: analysis of programmed death ligand 1 immunohistochemistry expression in gastric cancer biopsies” by Prof. Sunil Badve, Head of the Department of Pathology and Laboratory Medicine at Emory University School of Medicine (Atlanta, USA).
SOURCE: Presse Box
